TY - JOUR
T1 - Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors
T2 - a pilot randomized double-blind controlled clinical trial (VOLUME RCT)
AU - Kang, Danbee
AU - Kim, Im Ryung
AU - Park, Yeon Hee
AU - Im, Young Hyuck
AU - Zhao, Di
AU - Guallar, Eliseo
AU - Ahn, Jin Seok
AU - Cho, Juhee
N1 - Funding Information:
This work was supported by Legacy Healthcare and Basic Science Research Program of the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2017R1D1A1B03031654).
Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Purpose: This study aimed to evaluate the impact of a topical lotion (CG428) on hair thickness and density in breast cancer survivors with permanent chemotherapy-induced alopecia (PCIA). Methods: The study was a double-blind, randomized controlled trial which conducted from February 2016 to December 2016 at the Samsung Comprehensive Cancer Center in Seoul, South Korea. Breast cancer patients with PCIA were randomized on average of 3.5 years after chemotherapy. Topical lotion (Batch DT023) is a botanical drug under development containing a novel patented blend of 4 botanical ingredients: citrus, cocoa, guarana, and onion. Participants were asked to self-apply the study product or placebo twice per day for 6 months. Changes in hair density and thickness were assessed using a noninvasive bioengineering device, and patient-reported outcomes were evaluated at 3 and 6 months after randomization. Results: A total of 35 patients were randomized to intervention (N = 18) or placebo (N = 17). Patients in the intervention group were older than those in the placebo group (52.1 vs. 41.6 years; P < 0.001). The mean hair density (SD) at baseline was 97.6 (6.4) and 126.8 (30.3) hairs/cm2 in the intervention and placebo group, respectively (P = 0.005). The corresponding values for hair thickness were 49.9 (12.7) and 48.1 (8.4) μm, respectively. After 6 months, hair density had increased by 34.7 and 24.9% compared with baseline in the intervention and control groups, respectively (P = 0.37). Corresponding values for hair thickness were 19.8 and 35.6%, respectively (P = 0.23). Similar findings were observed after age adjustment. Discussion: In this pilot randomized clinical trial, we observed safety, tolerability, and a trend toward the efficacy of CG428 vs. placebo, especially regarding hair density and self-reported improvement.
AB - Purpose: This study aimed to evaluate the impact of a topical lotion (CG428) on hair thickness and density in breast cancer survivors with permanent chemotherapy-induced alopecia (PCIA). Methods: The study was a double-blind, randomized controlled trial which conducted from February 2016 to December 2016 at the Samsung Comprehensive Cancer Center in Seoul, South Korea. Breast cancer patients with PCIA were randomized on average of 3.5 years after chemotherapy. Topical lotion (Batch DT023) is a botanical drug under development containing a novel patented blend of 4 botanical ingredients: citrus, cocoa, guarana, and onion. Participants were asked to self-apply the study product or placebo twice per day for 6 months. Changes in hair density and thickness were assessed using a noninvasive bioengineering device, and patient-reported outcomes were evaluated at 3 and 6 months after randomization. Results: A total of 35 patients were randomized to intervention (N = 18) or placebo (N = 17). Patients in the intervention group were older than those in the placebo group (52.1 vs. 41.6 years; P < 0.001). The mean hair density (SD) at baseline was 97.6 (6.4) and 126.8 (30.3) hairs/cm2 in the intervention and placebo group, respectively (P = 0.005). The corresponding values for hair thickness were 49.9 (12.7) and 48.1 (8.4) μm, respectively. After 6 months, hair density had increased by 34.7 and 24.9% compared with baseline in the intervention and control groups, respectively (P = 0.37). Corresponding values for hair thickness were 19.8 and 35.6%, respectively (P = 0.23). Similar findings were observed after age adjustment. Discussion: In this pilot randomized clinical trial, we observed safety, tolerability, and a trend toward the efficacy of CG428 vs. placebo, especially regarding hair density and self-reported improvement.
KW - Botanical
KW - Breast neoplasm
KW - Chemotherapy
KW - Hair density
KW - Hair thickness
KW - Permanent chemotherapy-induced alopecia
KW - Topical lotion
UR - http://www.scopus.com/inward/record.url?scp=85069673631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069673631&partnerID=8YFLogxK
U2 - 10.1007/s00520-019-04982-z
DO - 10.1007/s00520-019-04982-z
M3 - Article
C2 - 31338640
AN - SCOPUS:85069673631
SN - 0941-4355
VL - 28
SP - 1829
EP - 1837
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 4
ER -